A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behcet Disease.

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behcet Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Behcet's syndrome; Oral ulcer
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 15 Apr 2015 According to Celgene Corporation media release, based on the results of this trial, company has filed with regulatory authorities in Turkey.
    • 15 Apr 2015 Results published in The New England Journal of Medicine, as per Celgene Corporation media release.
    • 26 Sep 2013 Results from this trial will be presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting according to a Celgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top